Big Pharma Oncology Strategies Aim To Treat Cancer Earlier

Combinations May Advance Novel Drugs Faster

 
• By Mandy Jackson
  
Generate a summary of this article
Listen to this article
Beta

ADCs, radiopharmaceuticals, precision medicines and T-cell engagers dominated R&D pipelines reviewed by 12 big pharmas at the first annual AACR Oncology Industry Partnering Event.

A 3D illustration depicting Cancer Cells in the crosshairs, related to cancer treatment
Pharma firms are pursuing new ways of addressing known targets • Source: Shutterstock

Presentations from 12 big pharma companies at a pre-AACR event highlighted common interests in therapeutic modalities that have driven recent dealmaking in the industry – antibody-drug conjugates (ADCs) and radiopharmaceuticals, for instance – and a growing desire to bring novel medicines to earlier lines of cancer treatment sooner. The companies were invited to an inaugural partnering meeting ahead of the American Association for Cancer Research annual conference in San Diego to outline their oncology research and development strategies in a way that might highlight inroads for future collaborators.

Key Takeaways

  • Twelve big pharma companies presented their cancer drug R&D strategies during the inaugural AACR Oncology Industry Partnering Event from 4 to 5 April in San Diego.

The AACR Oncology Industry Partnering Event took place 4-5 April, before the start of the AACR annual meeting on 7...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Anticancer

Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

 
• By Xu Hu

Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]

Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.

Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

Allarity Hopes To Breathe New Life Into Ixempra In Breast Cancer

The US precision medicine company hopes its drug response predictor technology will enhance responses to the chemotherapy Ixempra on the basis of promising data from a handful of breast cancer patients in a Phase II trial, marking a positive turn in its journey to date.  

More from Therapeutic Category

Scrip Data Article Without An Author

"Neque porro quisquam est qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit..."

Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]

Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.

Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.